merck the world's largest drugs group will today reveal it is developing a new compound to treat enlarged prostate a condition that affects 50 per cent of men over 60 and 70 per cent over 70 more than 10 m americans are affected by the disease dr roy vagelos chairman and chief executive and dr edward scolnick president of merck research laboratories will present analysts with early clinical data about the new compound showing that it is effective the new drug if successfully developed will prove an important element in merck's growing prostate franchise merck has already developed a compound called proscar to treat the condition also known as benign prostatic hyperplasia however the drug has struggled to generate expected sales specialists have been concerned about the drug's effectiveness although they admit the safety profile is excellent the condition which involves the enlarged prostate obstructing the flow of urine from the bladder through the penis causing the need for frequent and urgent urination is normally treated by surgery